We demonstrated that the cancer-specific EGFR targeted immunotoxin, hDT806, was able to act as a stimulator of the tumor-intrinsic innate immune response by activating the STING-IFN-I axis in both HNSCC cells as well as xenograft tumor models. This evidence concerns the gene EGFR and cancer.